Published in Ann Rheum Dis on November 25, 2011
Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol (2014) 1.24
Characterizing IgG4-related disease with ¹⁸F-FDG PET/CT: a prospective cohort study. Eur J Nucl Med Mol Imaging (2014) 1.21
Histopathologic Overlap between Fibrosing Mediastinitis and IgG4-Related Disease. Int J Rheumatol (2012) 1.12
IgG4-related kidney disease--an update. Curr Opin Nephrol Hypertens (2015) 1.11
Spectrum of Disorders Associated with Elevated Serum IgG4 Levels Encountered in Clinical Practice. Int J Rheumatol (2012) 1.06
[IgG4-related disease]. Z Rheumatol (2013) 0.97
Eosinophilic granulomatosis with polyangiitis: an overview. Front Immunol (2014) 0.95
Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). PLoS One (2015) 0.89
Increased IgG4-Positive Plasma Cells in Granulomatosis with Polyangiitis: A Diagnostic Pitfall of IgG4-Related Disease. Int J Rheumatol (2012) 0.89
Biomarkers in vasculitis. Curr Opin Rheumatol (2014) 0.86
Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. Oncoimmunology (2015) 0.82
Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial. J Neurol (2015) 0.81
Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther (2013) 0.77
[Update Churg-Strauss syndrome]. Z Rheumatol (2012) 0.75
Erdheim-Chester Disease as a Mimic of IgG4-Related Disease: A Case Report and a Review of a Single-Center Cohort. Medicine (Baltimore) (2016) 0.75
Overview of IgG4-Related Tubulointerstitial Nephritis and Its Mimickers. J Pathol Transl Med (2015) 0.75
Alveolar haemorrhage in eosinophilic granulomatosis and polyangiitis (Churg-Strauss). Clin Rheumatol (2014) 0.75
[Clinical spectrum of IgG4-related diseases and the connection to rheumatology]. Z Rheumatol (2016) 0.75
The pathogenesis of rheumatoid arthritis. N Engl J Med (2011) 12.16
Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol (2007) 8.47
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med (2012) 6.93
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med (2009) 6.61
Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol (2007) 6.13
Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest (2012) 4.31
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol (2005) 3.80
Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet (2011) 3.19
Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum (2007) 3.02
Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med (2008) 2.97
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest (2002) 2.85
Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol (2010) 2.70
Autophagy regulates TNFα-mediated joint destruction in experimental arthritis. Ann Rheum Dis (2012) 2.66
Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun (2012) 2.65
Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol (2012) 2.59
Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum (2010) 2.54
MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum (2010) 2.53
Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum (2002) 2.52
Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol (2015) 2.39
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum (2005) 2.32
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21
Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) (2009) 2.14
Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum (2007) 2.12
High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med (2006) 2.09
Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation (2004) 2.08
Relations of vitamin D status, gender and type 2 diabetes in middle-aged Caucasians. Acta Diabetol (2014) 2.07
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis (2012) 2.06
12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity (2012) 2.06
Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med (2011) 2.05
Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum (2009) 2.04
Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A (2011) 1.95
Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum (2004) 1.94
Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res (2004) 1.88
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis (2014) 1.88
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer (2011) 1.83
Detection of "Candidatus Neoehrlichia mikurensis" in two patients with severe febrile illnesses: evidence for a European sequence variant. J Clin Microbiol (2010) 1.82
Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis. Ann Rheum Dis (2012) 1.81
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis (2012) 1.78
HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum (2007) 1.76
Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford) (2011) 1.74
How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum (2008) 1.74
Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum (2002) 1.72
Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum (2013) 1.69
Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford) (2011) 1.68
Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis (2010) 1.67
PPARβ/δ governs Wnt signaling and bone turnover. Nat Med (2013) 1.66
Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum (2009) 1.65
Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum (2007) 1.62
TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A (2007) 1.61
Wnt inhibitory factor 1 deficiency uncouples cartilage and bone destruction in tumor necrosis factor α-mediated experimental arthritis. Arthritis Rheum (2013) 1.59
Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis (2007) 1.58
Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis. Ann Rheum Dis (2012) 1.58
The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis (2013) 1.57
Pachydermodactyly: a review. Curr Rheumatol Rep (2014) 1.56
Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis (2011) 1.56
T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Sci Transl Med (2014) 1.56
Mechanisms of Disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol (2005) 1.55
Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum (2004) 1.53
Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum (2004) 1.53
Technical aids in the diagnosis of brain death: a comparison of SEP, AEP, EEG, TCD and CT angiography. Dtsch Arztebl Int (2012) 1.53
Antibodies to the endoplasmic reticulum-resident chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and systemic lupus erythematosus. Rheumatology (Oxford) (2010) 1.53
The role of Wnt proteins in arthritis. Nat Clin Pract Rheumatol (2008) 1.52
Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther (2011) 1.51
Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss. J Bone Miner Res (2012) 1.49
Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis. Arthritis Rheumatol (2014) 1.48
Segmentation and quantification of bone erosions in high-resolution peripheral quantitative computed tomography datasets of the metacarpophalangeal joints of patients with rheumatoid arthritis. Rheumatology (Oxford) (2013) 1.48
Osteitis and synovitis, but not bone erosion, is associated with proteoglycan loss and microstructure damage in the cartilage of patients with rheumatoid arthritis. Ann Rheum Dis (2013) 1.47